Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

This study has been completed.

Study NCT00041106 Information provided by Cancer and Leukemia Group B

First Received: July 8, 2002 Last Updated: March 22, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	June 2010
Primary Completion Date:	July 2007 (Final data collection date for primary outcome measure)

Publications:

Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ; for the Cancer and Leukemia Group B. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol. 2009 Jan 23; [Epub ahead of print]

Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ; Cancer and Leukaemia Group B. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int. 2007 Oct 8; [Epub ahead of print]

Philips G, Sanford B, Halabi S, et al.: Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): analysis of the second cohort of CALGB 90102. [Abstract] J Clin Oncol 24 (Suppl 18): A-4578, 2006.

Philips G, Halabi S, Sanford B, et al.: Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: preliminary results of CALGB 90102. [Abstract] J Clin Oncol 22 (Suppl 14): A-4540, 391s, 2004.